Literature DB >> 2372659

Effects of various neuropeptide Y/peptide YY fragments on electrically-evoked contractions of the rat vas deferens.

L Grundemar1, R Håkanson.   

Abstract

1. The effects of various neuropeptide Y (NPY) and peptide YY (PYY) fragments on electrically-evoked twitches in the rat isolated vas deferens were studied and compared with the effects of full length NPY and PYY. The aim was to identify the shortest NPY/PYY fragments that are capable of suppressing the contractions. 2. NPY (1-36) and C-terminal fragments of NPY (from 11-36 to 22-36) suppressed the electrically-evoked twitches in a concentration-dependent manner. On the whole there seemed to be a gradual lowering of the pIC50 values with progressive shortening of the NPY fragments (except for fragments 16-36 and 22-36 that had rather high pIC50 values). NPY 23-36, 24-36 and 25-36 suppressed the twitches at high concentrations (3 microM). NPY 26-36 was without effect as were C-terminal carboxy-deaminated NPY and glycine extended NPY (NPY-Gly-Lys-Arg). 3. PYY (1-36) and C-terminal fragments of PYY (from 11-36 to 23-36) suppressed the electrically-evoked twitches in a concentration-dependent manner. PYY 1-36 was more potent than any of the fragments. There was a tendency for shorter fragments to have lower pIC50 values. PYY 24-36 and 25-36 suppressed the twitches at high concentrations (3 microM). PYY 26-36 was without effect. 4. The findings suggest that the 12 C-terminal amino acid residues of NPY and PYY are the minimum length required to activate the Y2-receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2372659      PMCID: PMC1917462          DOI: 10.1111/j.1476-5381.1990.tb12075.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Neuropeptide Y-like immunoreactivity in perivascular nerve fibres of the guinea-pig.

Authors:  R Uddman; E Ekblad; L Edvinsson; R Håkanson; F Sundler
Journal:  Regul Pept       Date:  1985-03

2.  Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide.

Authors:  K Tatemoto; M Carlquist; V Mutt
Journal:  Nature       Date:  1982-04-15       Impact factor: 49.962

3.  Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function.

Authors:  J M Lundberg; L Terenius; T Hökfelt; C R Martling; K Tatemoto; V Mutt; J Polak; S Bloom; M Goldstein
Journal:  Acta Physiol Scand       Date:  1982-12

4.  Highly potent and small neuropeptide Y agonist obtained by linking NPY 1-4 via spacer to alpha-helical NPY 25-36.

Authors:  A Beck; G Jung; W Gaida; H Köppen; R Lang; G Schnorrenberg
Journal:  FEBS Lett       Date:  1989-02-13       Impact factor: 4.124

5.  Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility.

Authors:  J M Lundberg; K Tatemoto; L Terenius; P M Hellström; V Mutt; T Hökfelt; B Hamberger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

6.  Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers.

Authors:  E Ekblad; L Edvinsson; C Wahlestedt; R Uddman; R Håkanson; F Sundler
Journal:  Regul Pept       Date:  1984-04

7.  Neuropeptide Y (NPY) depresses the secretion of 3H-noradrenaline and the contractile response evoked by field stimulation, in rat vas deferens.

Authors:  J M Lundberg; L Stjarne
Journal:  Acta Physiol Scand       Date:  1984-03

8.  Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut.

Authors:  G Böttcher; K Sjölund; E Ekblad; R Håkanson; T W Schwartz; F Sundler
Journal:  Regul Pept       Date:  1984-07

9.  Conformational studies on the pancreatic polypeptide hormone family.

Authors:  I D Glover; D J Barlow; J E Pitts; S P Wood; I J Tickle; T L Blundell; K Tatemoto; J R Kimmel; A Wollmer; W Strassburger
Journal:  Eur J Biochem       Date:  1984-07-16

10.  The vasoconstrictor effect of neuropeptide Y and related peptides in the guinea pig isolated heart.

Authors:  F Rioux; H Bachelard; J C Martel; S St-Pierre
Journal:  Peptides       Date:  1986 Jan-Feb       Impact factor: 3.750

  10 in total
  7 in total

1.  Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by a Y2 receptor.

Authors:  W F Colmers; G J Klapstein; A Fournier; S St-Pierre; K A Treherne
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

Review 2.  Neuropeptide Y Y2 receptor in health and disease.

Authors:  S L Parker; A Balasubramaniam
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

3.  Neuropeptide Y, peptide YY and C-terminal fragments release histamine from rat peritoneal mast cells.

Authors:  L Grundemar; R Håkanson
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

4.  The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: an analysis of the contribution of Y1 and Y2 receptors.

Authors:  Duc Quyen Chu; Helen M Cox; Soraia K P Costa; Herbert Herzog; Susan D Brain
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

5.  Functional effects and ligand binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types.

Authors:  U Kahl; U Langel; T Bartfai; L Grundemar
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

6.  Characterization of vascular neuropeptide Y receptors.

Authors:  L Grundemar; S E Jonas; N Mörner; E D Högestätt; C Wahlestedt; R Håkanson
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

7.  Purification and Biochemical Characterization of TsMS 3 and TsMS 4: Neuropeptide-Degrading Metallopeptidases in the Tityus serrulatus Venom.

Authors:  Daniela Cajado-Carvalho; Cristiane Castilho Fernandes da Silva; Roberto Tadashi Kodama; Douglas Oscar Ceolin Mariano; Daniel Carvalho Pimenta; Bruno Duzzi; Alexandre Kazuo Kuniyoshi; Fernanda Vieira Portaro
Journal:  Toxins (Basel)       Date:  2019-03-31       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.